Ladenburg analyst Kevin Degeeter initiated coverage of Novocure (NVCR) with a Buy rating and $30 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Promising Phase 3 Results for NovoCure’s TTFields Therapy in Pancreatic Cancer
- Novocure to present final secondary endpoint results from PANOVA-3 trial
- Novocure management to meet with Piper Sandler
- NovoCure Appoints New President at Annual Meeting
- Novocure data support pancreatic cancer approval, says Wells Fargo